Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology
-$0.04 today
- Market cap
- $52.19M
- Beta
- 0.76
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.16
Volume 0.23M
Average 1.15M
RANI Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Rani Therapeutics Holdings, Inc.NASDAQ: RANI
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $4.89M fell 13.0% year over year, ahead of the -17.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.0% from the prior quarter. Over 3 fiscal years it compounded at -9.7% a year.
Context
- Selling, general & admin amounted to 1208.7% of revenue in FY2025, down 1120.7 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $59.64M (+202.2%) for the fiscal year ending Dec 2026, a step up from the -17.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.89M-4.0% QoQ
- Last fiscal yearDec 2025
- $19.74M-17.6% YoY
- LTMMar 2026
- $19.01M-17.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 19.74M USD
- Year-over-year change
- -17.6%
- 4-year CAGR
- -8.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.74M | -17.6% |
| FY2024 | 2024-12-31 | 23.95M | -9.6% |
| FY2023 | 2023-12-31 | 26.48M | -1.4% |
| FY2022 | 2022-12-31 | 26.84M | -3.6% |
| FY2021 | 2021-12-31 | 27.83M | — |
Selling, General & Admin vs competitors
How RANI compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -17.8% is the 8th highest of 9, against a peer median of -4.1%.
- Selling, general & admin amounts to 599.8% of revenue for RANI, versus a peer median of 394.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $63.26M USD | +90.6% | +41.6% | 360.3% | |
| LTM Mar 2026 | $34.83M USD | -4.4% | -11.4% | 1952.5% | |
| LTM Mar 2026 | $31.65M USD | -26.4% | -17.7% | 91.6% | |
| LTM Mar 2026 | $19.01M USD | -17.8% | -9.7% | 599.8% | |
| LTM Mar 2026 | CHF 16.11M CHF | -3.8% | -12.0% | — | |
| LTM Mar 2026 | $15.52M USD | -5.5% | -6.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $13.7M USD | +20.3% | +31.5% | — |
| LTM Mar 2026 | $13.02M USD | +27.1% | +2.6% | 2479.6% | |
| FY2025 | €11M EUR | -7.8% | -8.7% | 394.7% | |
| Peer median (excluding RANI) | — | -4.1% | -7.7% | 394.7% | |
Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.72M | 0 | 0 | 1.03M | 1.63M |
| Cost of Revenue | 0 | 0 | 822K | 0 | 900K |
| Gross Profit | 2.72M | 0 | (822K) | 1.03M | 733K |
| Gross Margin | 100.0% | — | — | 100.0% | 44.9% |
| Research & Development | 26.48M | 36.61M | 39.62M | 26.68M | 20.21M |
| Selling, General & Admin | 27.83M | 26.84M | 26.48M | 23.95M | 19.74M |
| Operating Expenses | 54.32M | 63.45M | 65.28M | 54.34M | 39.04M |
| Depreciation & Amortization | 497K | 548K | 822K | 1.03M | 900K |
| EBITDA | (52.08M) | (61.66M) | (61.98M) | (50.52M) | (37.16M) |
| EBITDA Margin | -1917.0% | — | — | -4914.7% | -2275.5% |
| Operating Income | (51.6M) | (63.45M) | (66.1M) | (53.31M) | (38.31M) |
| Operating Margin | -1899.1% | — | — | -5186.2% | -2346.0% |
| Interest Income | 89K | 1.25M | 3.3M | 1.76M | 827K |
| Interest Expense | 466K | 1.07M | 5.09M | 5.03M | 2.89M |
| Other Income / Expenses | (1.45M) | 177K | (1.78M) | 23.3M | (2.64M) |
| Income Before Tax | (53.05M) | (63.27M) | (67.88M) | (30.02M) | (40.95M) |
| Pre-Tax Margin | -1952.4% | — | — | -2920.0% | -2507.7% |
| Income Tax Expense | 41K | 70K | 0 | 26.57M | 0 |
| Net Income | (8.33M) | (30.59M) | (33.97M) | (30.02M) | (29.67M) |
| Net Margin | -306.6% | — | — | -2920.0% | -1817.1% |
| EPS (Basic) | (0.42) | (1.28) | (1.33) | (1.05) | (0.45) |
| EPS (Diluted) | (0.42) | (1.28) | (1.33) | (1.05) | (0.45) |
| Weighted Avg Shares | 19.53M | 23.82M | 25.51M | 28.48M | 66.14M |
| Weighted Avg Shares (Diluted) | 19.53M | 23.82M | 25.51M | 28.48M | 66.14M |
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.